glp-1 pancreatitis risk GLP-1–Based Therapies: The Dilemma of Uncertainty Updates in Medicine | GLP-1s

Carrying extra weight, particularly around the abdomen, is one of the most significant modifiable risk factors for vein disease

Explaining this to patients also serves as an educational opportunity to highlight the relationship between dietary patterns and blood glucose levels

Because liraglutide shares 97% homology with GLP-1 while exenatide only shares 50% of GLP-1, it is inferred that liraglutide is more likely to mimic the function of endogenous GLP-1

Injectable formulations dominate the market with a 74% share, driven by their proven efficacy and reliability in delivering GLP-1 analogues

See the 2024 KDIGO guidelines [17]